Drug profile
Selexipag
GenericRadar assessment
Patent Radar Assessment
Grade B1
United States · 2030 Radar
Verification
HIGH
Why not A?
Not Grade A: US8791122 is explicitly directed to the Form-I crystal of selexipag. The original compound patent family represented by US7205302 reaches its U.S. protection endpoint earlier, so the 2030 event is a crystal-form lifecycle patent rather than the original composition-of-matter cliff.
Core Patent Expiry
2026-10-31
2030 Target Event
US8791122
Polymorph / Form-I Crystal · 2030-08-01
Core API Event?
No
Later Blocking Patents
Yes. UPTRAVI has later product/use patent events extending to 2036-2037.
Generic Entry Assessment
High-value B1 event because the marketed solid form may matter for API sourcing and formulation, but it must not be presented as the original API patent expiry.
Patent landscape
| Country | Patent no. | Type | Expiry | Status | Verified | Opportunity |
|---|---|---|---|---|---|---|
| United States | US8791122 | Polymorph / Form-I Crystal | 2030-08-01 | Protected | Yes | 41 |
API sourcing
Regulatory filing labels distinguish verified/listed records from records that have not yet been verified. “Not verified” does not mean that a filing does not exist.
| API | Manufacturer | Country | US DMF | KDMF | Japan MF | CEP | EU GMP | Status |
|---|---|---|---|---|---|---|---|---|
| Selexipag | No supplier linked | — | — | — | — | Not verified | — |